Research and Markets (http://www.researchandmarkets.com/research/76x5rk/safinamide)
has announced the addition of the "Safinamide
(Parkinson's Disease) - Forecast and Market Analysis to 2022"
report to their offering.
In 2012, Newron completed Phase III clinical trials for safinamide, a
dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate
release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck
Serono (a division of Merck KGaA) had acquied the exclusive worldwide
rights for safinamide; however, in 2011 the deal was terminated, seeing
Merck returning the compound to Newron due to concerns over the
potential market size for the drug.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/76x5rk/safinamide
[ Back To NFVZone's Homepage ]